UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan

Leslie E. Carlini, Neal J. Meropol, John Bever, Michael L. Andria, Todd Hill, Philip Gold, Andre Rogatko, Hao Wang, Rebecca L. Blanchard

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan'. Together they form a unique fingerprint.

Medicine & Life Sciences